Vaxcyte Inc annual operating income for fiscal TTM was -$1.2 billion, a decrease of 26.1% from -$924 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($1.2B) | ($924M) | ($570M) | ($468M) | ($232M) | ($104M) | ($90M) | ($54M) | ($36M) | ($18M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($303M) | ($346M) | ($274M) | ($242M) | ($226M) | ($181M) | ($162M) | ($140M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More PCVX metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All PCVX financial statements → Interactive PCVX charts →
About TickerBase · Data methodology & sources · Privacy · Terms